Tirilazad
Systematic (IUPAC) name | |
---|---|
(16α)-21-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]-16-methylpregna-1,4,9(11)-triene-3,20-dione | |
Identifiers | |
CAS Number | 110101-66-1 |
ATC code | N07XX01 (WHO) |
PubChem | CID 104903 |
ChemSpider | 94673 |
UNII | YD064E883I |
KEGG | D08606 |
ChEMBL | CHEMBL1630578 |
Synonyms | (8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one |
Chemical data | |
Formula | C38H52N6O2 |
Molar mass | 624.859 g/mol |
| |
| |
(what is this?) (verify) |
Tirilazad is a drug that has been proposed to treat acute ischaemic stroke. When tested on animal models, tirilazad protects brain tissue, and reduces brain damage. However, the drug fails to treat, and even worsens a stroke when studied on a human being.[1]
Usage in treatment of stroke
Tirilazad currently has no usage in the clinical treatment of stroke.
References
- ↑ "Tirilazad for acute ischaemic stroke". Retrieved 2007-07-28.
|
This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.